Back to Authors

Christensen, Jon

A5023566325 | I204465549

Mayo Clinic

Washington University in St. Louis

Citations 6

Tau PET in autosomal dominant Alzheimer’s disease: relationship with cognition, dementia and other biomarkers

Brain | January 29, 2019 | Volume: 142 | Issue: 4 | Pages: 1063-1076

10.1093/brain/awz019 | PMID 30753379

O3‐13‐03: THE RELATIONSHIP BETWEEN TAU PET AND OTHER AD BIOMARKERS IN AUTOSOMAL DOMINANT ALZHEIMER DISEASE

Alzheimer's & Dementia | October 22, 2018 | Volume: 14 | Issue: 7S_Part_19 | Pages: No page available

10.1016/j.jalz.2018.06.2845

IC‐P‐204: THE RELATIONSHIP BETWEEN TAU PET AND OTHER AD BIOMARKERS IN AUTOSOMAL DOMINANT ALZHEIMER DISEASE

Alzheimer's & Dementia | October 22, 2018 | Volume: 14 | Issue: 7S_Part_3 | Pages: No page available

10.1016/j.jalz.2018.06.2271

[O1–02–03]: EXAMINING LONGITUDINAL NEUROIMAGING PATTERNS IN AUTOSOMAL DOMINANT ALZHEIMER DISEASE: FINDINGS FROM THE DOMINANTLY INHERITED ALZHEIMER NETWORK

Alzheimer's & Dementia | October 20, 2017 | Volume: 13 | Issue: 7S_Part_3 | Pages: No page available

10.1016/j.jalz.2017.07.041

[IC‐P‐054]: EXAMINING LONGITUDINAL NEUROIMAGING PATTERNS IN AUTOSOMAL DOMINANT ALZHEIMER DISEASE: RESULTS FROM THE DOMINANTLY INHERITED ALZHEIMER NETWORK

Alzheimer's & Dementia | October 20, 2017 | Volume: 13 | Issue: 7S_Part_1 | Pages: No page available

10.1016/j.jalz.2017.06.2327

Regional variability of imaging biomarkers in autosomal dominant Alzheimer’s disease

Proceedings of the National Academy of Sciences | November 5, 2013 | Volume: 110 | Issue: 47 | Pages: No page available

10.1073/pnas.1317918110 | PMID 24194552

Significance Beta-amyloid plaque accumulation, glucose hypometabolism, and neuronal atrophy are hallmarks of Alzheimer’s disease. However, the regional ordering of these biomarkers prior to dementia remains untested. In a cohort with Alzheimer’s disease mutations, we performed an integrated whole-brain analysis of three major imaging techniques: amyloid PET, [ 18 F]fluro-deoxyglucose PET, and structural MRI. We found that most gray-matter structures with amyloid plaques later have hypometabolism followed by atrophy. Critically, however, not all regions lose metabolic function, and not all regions atrophy, even when there is significant amyloid deposition. These regional disparities have important implications for clinical trials of disease-modifying therapies.